dihydropyrimidine dehydrogenase (dpd)

TAS-114 is an orally active dual inhibitor of dUTPase and dihydropyrimidine dehydrogenase (DPD). TAS-114 targets the intercellular metabolism of 5-FU to enhance antitumor activity and modulates catabolic pathways to improve the systemic availability of 5-FU.

Eniluracil (GW776C85) is an orally activedihydropyrimidine dehydrogenase (DPD) inhibitor,increases the oral bioavailability of 5-FU to 100%, facilitating uniform absorption and predictable toxicity.

Gimeracil (Gimestat) is a competitive, reversible inhibitor of dihydropyrimidine dehydrogenase.

5,6-Dihydrouracil (5,6-Dihydrouracil) is an intermediate breakdown product of uracil.

(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), which can be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner, enhancing the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, thereby increasing survival time.

5,6-Dihydrouracil-D4 is the deuterated form of 5,6-Dihydrouracil (T4886). Dihydrouracil itself is a metabolite of uracil and serves as a marker for identifying deficiencies in dihydropyrimidine dehydrogenase (DPD).

Gimeracil (Standard) is a reference standard for research and analysis in studies involving Gimeracil. Gimeracil (Gimestat) is a competitive, reversible inhibitor of dihydropyrimidine dehydrogenase.